NONOF

Novo Nordisk has seen its share price fall sharply in recent years, which puts fresh focus on whether the current US$40.00 level is still aligned with what its earnings can justify.

Eli Lilly trial data showing retatrutide outperforming Ozempic has sharpened the competitive focus on Novo Nordisk (NYSE:NVO), just as the Danish drugmaker outlines longer term 2030 goals.

Novo Nordisk (NYSE:NVO) set new 2030 business targets as it responds to rising competition in GLP-1 diabetes and obesity drugs.

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The company’s comeback strategy looks sound.

Novo Nordisk (NYSE:NVO) faces tougher GLP-1 competition after Lilly’s retatrutide outperformed Ozempic in a diabetes trial, Citi said, maintaining its ‘neutral/high risk’ rating and a Dkr296.00 target price.

Eli Lilly just posted a quarter that left its GLP-1 rivals in the dust, but margin pressure and a $900 million pile of one-time benefits raise questions about how much of that strength is real and how long it can last.

Novo Nordisk has seen its share price come under pressure, and the question for you now is whether the current valuation is still supported by the earnings power of the business.

Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday.

Novo Nordisk today announced that 12 new abstracts on semaglutide real-world and clinical data will be presented at the American Association for the Study of Liver Diseases congress, The Liver Meeting® 2026, from November 5-9 in Denver, Colorado.

Retatrutide helped patients with type 2 diabetes lose an average of 44 to 47 pounds over 80 weeks, compared with about 21 pounds for Ozempic.

In the latest trading session, Novo Nordisk (NVO) closed at $38.7, marking a -1.11% move from the previous day.